YALE CENTER FOR GENOME ANALYSIS SHARED RESOURCE PROJECT SUMMARY/ABSTRACT The Yale Center for Genome Analysis (YCGA) was established in 2010 to provide next-generation sequencing (NGS), single-cell genomics, and microarray support forYCC members. The Center is a full-service facility dedicated to providing RNA expression profiling, DNA genotyping, and next-Gen DNA sequencing and related state-of-the-art technologies. Full microarray and next-generation sequencing services provided by YCGA include: DNA and RNA isolation from tissue and blood; sample preparation ready for microarray and next-Gen sequence (NGS) analysis; providing primary data; full-time YCC-supported staff for downstream bioinformatics data analysis, working collaboratively with YCC investigators and providing methods and other write-ups for grants. Additionally, the staff has obtained equipment and center grants to reduce the cost of sequencing. During the most recent funding period, 211 people have used YCGA Eighty-seven of these users (41%) were YCC members. The majority of this use came from Genomics, Genetics and Epigenetics (GGE). YCGA provides free consultation and training for YCC members. The core is led by Director Shrikant Mane, PhD, Professor of Genetics, whose experience is complemented by the strong expertise of Associate Director Kaya Bilguvar, MD, PhD.
The Specific Aims of YCGA are to provide: (1) Next-generation sequencing services using multiple sequencing platforms, including Illumina, Ion Torrent, and Pacific Biosciences; (2) Microarray services using Affymetrix and Illumina platforms for gene expression, genotyping, and methylation assays; (3) Single cell genomics and structural variation determination using the 10X Genomics platform; (4) Research and development. YCGA continuously carries out biotechnology research to develop improved methodologies and tools, to test the relative merits of new technologies, and to generate preliminary results for NIH grants. (5) Bioinformatics. Dr. Francesc Lopez supports the secondary analysis needs of YCC members. His salary is supported by YCC. (6) Consultation. YCGA makes every effort to develop collaborative relationships with its users, and takes interest in their scientific projects. (7) Education and training. Staff members actively participate in YCC Grand Rounds, departmental seminars, and YSM Dean?s workshops aimed at providing principles and technical details of the various genomic technologies.
|Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326|
|Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083|
|Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291|
|Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40|
|Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631|
|Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025|
|Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461|
|Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853|
|Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573|
|Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331|
Showing the most recent 10 out of 675 publications